A Double-blind Study of Controlled Release OROS Hydromorphone Compared to Placebo in Patients With Chronic Osteoarthritis (OA) Pain

• Status: Completed
• Trial end date: 2009-06-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the efficacy of OROS Hydromorphone in reducing moderate to severe chronic pain in patients with Osteoarthritis (OA) Pain

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mallinckrodt
• Treatments: Hydromorphone

Criteria

Inclusion Criteria

• Primary clinic diagnosis of osteoarthritis pain of the hip or of the knee for at least 6 months

• Patients required daily opioid medication to treat their chronic osteoarthritis pain

Exclusion Criteria

• Joint replacement of the hip or of the knee that is the primary source of osteoarthritis Pain

• History drug or alcohol abuse

• Fibromyalgia

• Patients who have major depression or anxiety

• Women who are pregnant or breast feeding